Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Small Cell 1

Interventions

pembrolizumab 134Carboplatin 134Cisplatin 121Paclitaxel 105Gemcitabine 89Specimen Handling 82Magnetic Resonance Spectroscopy 82Docetaxel 74Cyclophosphamide 61Dexamethasone 60Pemetrexed 58Bevacizumab 56durvalumab 55Capecitabine 55Doxorubicin 52Radiotherapy 51Oxaliplatin 50Fluorouracil 49Radiation 48Rituximab 44Leucovorin 44Vincristine 42Lenalidomide 41Etoposide 39atezolizumab 37Nivolumab 37Letrozole 36130-nm albumin-bound paclitaxel 33Prednisone 31Irinotecan 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × EC regimen × 90 days × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡